3/28/2013

The FDA has given orphan-drug status to Acceleron Pharma's experimental beta-thalassemia and myelodysplastic syndrome treatment ACE-536. The red blood cell booster is being developed by Acceleron in partnership with Celgene.

Full Story:
Boston Herald

Related Summaries